Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ignaseclant - NMD Pharma

Next Previous
Drug Profile

Ignaseclant - NMD Pharma

Alternative Names: Bromophenoxyazole propanoic acid; NMD-670; NMDP-01; NMDP-02; NMDP-08

Latest Information Update: 24 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NMD Pharma
  • Class Oxazoles; Propionic acids; Small molecules
  • Mechanism of Action CLC-1 channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myasthenia gravis; Charcot-Marie-Tooth disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Charcot-Marie-Tooth disease; Myasthenia gravis; Spinal muscular atrophy
  • Preclinical Sarcopenia

Most Recent Events

  • 17 Jun 2026 Adverse events and efficacy data from the phase II SYNAPSE-CMT trial in Charcot Marie Tooth disease released by NMD Pharma
  • 18 May 2026 NMD Pharma completes a phase-II clinical trials in Spinal muscular atrophy in in the US,Belgium, Canada, Denmark, Germany, Italy, Netherlands and Spain (PO) (NCT05794139)
  • 10 Mar 2026 Adverse events and efficacy data from a a phase II SYNAPSE-CMT trial in Charcot Marie Tooth disease released by NMD Pharma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top